CAR T-Cell Cancer Therapy Potentially Linked to Rare Blood Cancer, Experts Respond

Some cancer patients on chimeric antigen receptor (CAR) T-cell therapy, a novel cancer treatment considered a breakthrough in the past decade, developed T lymphoma as an additional cancer—a very rare phenomenon. As of Dec. 6, 11 cases of T-cell lymphomas have been reported to the U.S. Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) Public Dashboard. The FDA is investigating the link. CAR T therapies are currently used to treat blood cancers, including multiple myelomas, leukemias, and B-cell lymphomas. “The potential risk of developing secondary malignancies is labeled as a class warning in the U.S. prescribing information (USPIs) for approved … genetically modified autologous T cell immunotherapies,” the FDA wrote in a press statement published Nov. 28....